ClinicalTrials.gg
Not yet recruitingNCT07632313Updated Jun 8, 2026

Health Behavior Intervention for Colorectal Cancer Patients

An interventional study of health behavior intervention programs based on the temporal self-regulation theory are also received in Colorectal Cancer, sponsored by Nanjing Medical University. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-06-08.

Sponsored by Nanjing Medical University · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

Develop a health behavior intervention plan based on patients' needs and preferences, and preliminarily apply and evaluate the feasibility and effectiveness of this intervention plan for patients with colorectal cancer.

02

Conditions studied

  • Colorectal Cancer

Keywords

  • health behavior
  • Temporal Self-Regulation Theory
03

In context

Colorectal Neoplasms

6,541 studies on the registry are indexed under Colorectal Neoplasms; 1,667 are open to participants now.

This study's planned enrollment of 40 is below the median of 76 across 4,800 interventional studies indexed under Colorectal Neoplasms.

Browse Colorectal Neoplasms studies →

Lead sponsor

Nanjing Medical University is the lead sponsor of 171 studies on the registry; 52 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Age ≥ 18 years; patients who meet the diagnostic criteria for colorectal cancer outlined in the "Chinese Guidelines for the Diagnosis and Treatment of Colorectal Cancer (2023 Edition)" and for whom the time since surgery is ≥ 3 months; patients who are able to understand the study and complete the questionnaire independently; and patients who voluntarily agree to participate.

Exclusion criteria

Exclusion Criteria:

Patients with severe cardiac, hepatic, or renal insufficiency or other serious systemic diseases; patients with cognitive or psychiatric disorders; patients with severe postoperative complications (such as anastomotic leakage or severe wound infection); patients with cancer or concurrent malignant tumors; patients with a of less than 6 months.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
Single (Participant)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    intervention group

    Based on providing routine post-operative health education services for colorectal cancer patients in the hospital, additional health behavior intervention programs based on the theory of time-limited self-regulation are also received.

    Behavioral: health behavior intervention programs based on the temporal self-regulation theory are also received

  • No intervention
    control group

    Regular post-operative health education services for colorectal cancer

Interventions

  • Behavioralhealth behavior intervention programs based on the temporal self-regulation theory are also received

    The intervention group received additional health behavior intervention programs based on the temporal self-regulation theory in addition to the routine post-operative health education services provided by the hospital. The intervention period was set as 1 session per week for a total of 6 weeks, each session lasting approximately 45-60 minutes. The intervention was conducted in a combination of offline and online guidance and support. Before the intervention, baseline assessments were conducted for the research subjects, and intervention manuals, demonstration videos, and other tools were distributed. From the 1st to the 5th week, corresponding module measures were implemented according to the intervention framework, including looking to the future, intention strengthening, habit shaping, and self-control. In the 6th week, progress summaries, feedback, and long-term plan formulation were carried out. Throughout the process, online WeChat/QQ support groups/Tencent Meeting were u

06

What researchers measure

Primary outcomes

  1. health behavior

    Measured through the Health Behavior Scale for Cancer Patient

    Time frame: From before the intervention (T0) to 3 months after the intervention (T2)

Secondary outcomes

  1. Health behavior intention

    Measured through the Health Behavior Intention Scale

    Time frame: From before the intervention (T0) to three months after the intervention (T2)

  2. Future Time Perspective

    Measured through the Consideration of Future Consequences Scale

    Time frame: From before the intervention (T0) to three months after the intervention (T2)

  3. Behavioral prepotency

    Measured through the Self-Reported Behavioral Automaticity Index

    Time frame: From before the intervention (T0) to three months after the intervention (T2)

07

Study locations

1 site
  • 101 Longmian Avenue, Jiangning District
    Nanjing, Jiangsu, China
08

References and documents

Individual participant data

Plan to share: No — IPD sharing is not allowed due to ethical and consent-related restrictions.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07632313
Responsible party
Xiaoxiao Hu (Xiaoxiao Hu, Nanjing Medical University) — Principal investigator
First posted
Jun 8, 2026
Start date
Jun 15, 2026 (estimated)
Primary completion
Dec 30, 2026 (estimated)
Completion
Jan 30, 2027 (estimated)
Last update
Jun 8, 2026

Study contacts

Xiao X Hu
Contact
1937505957@qq.com
+86 18752112918

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion